Intellicell Biosciences Inc (fka SVFC)

[Badrudy]

The autologous Vascular Fraction Cells developed by IntelliCell™ have several unique advantages:

As an autologous product, the donor of the tissue and the recipient of the cells are the same person. This fact highly reduces problems commonly associated with allogenic products. The risks of rejection are greatly reduced. The risks of allergic reaction are also highly reduced.
IntelliCell™ does not culture, grow, or expand the cells in any way. This is important to clinicians and patients alike. There is no growth serum used in the process, such as growing cells in bovine serum and there are no enzymatic agents in use, such as collagenese. IntelliCell™ thinks that its process results in a minimal manipulation of the originating vascular tissue and the final cellular product. Ultrasound, which has been in clinical use for decades, is the method by which IntelliCell™ is able to obtain the Vascular Fraction Cells.
The IntelliCell™ process also results in much higher cellular yields when compared to other methods in clinical research use today.
For the clinician using the IntelliCell™ product, it is a same day procedure. This is more convenient for the patient and the clinician.